2015 Journal

Transcription

2015 Journal

I
DO
want
change
I
DO
feel
hope
I DO
remember
him
I
DO
honor
her
I
DO
believe
in
clinical
t
r
i
a
l
s
I DO
I DO see progress I
the
word
I
DO
fight
I
DO
it
fellow
warriors
I
DO spread
join
the
for
my
DO
give
• • •
I DO support PHASE ONE
In memory of
Bernard and Wendy Goldhirsh
the Goldhirsh-Yellin Foundation
congratulates
Phase One
on their groundbreaking work
in cancer research.
PHASE ONE
Congratulations on many years
of great work!
Diane and Roger Duhl
We are proud to support
Phase One
•••
Kayne Foundation
Suzanne & Ric Kayne
Jenni Kayne-Ehrlich & Richard Ehrlich
In loving memory of
Tia Palermo Ravich
Jody and David
Lippman
I DO
I DO support PHASE ONE
• • •
th
15 Annual Gala
Thursday, April 30, 2015
Wallis Annenberg Center for the Performing Arts
• • •
FUNDING RESEARCH FOR 15 YEARS.
LET’S COMMIT TO 15 MORE.
EVENT COMMITTEE
•••
CO-CHAIRS
Meritt Elliott
Stacy Valner
Edyn Elliott Barber
Marci Foster
Mieke Neumann
Holly Baril
Maryann Gold
Elissa Phillips
Emily Bernstein
Angela Kay
Missy Polson
Leslie Birnbaum
Kaye Popofsky Kramer
Kimberly Reed
Marina Cohn
Brooke Lande
Stephanie Sandler
Leanna Creel
Dana Levine
Tema Schrage
Emily Current
Janet Lonner
Debra Silverstein
Natalie Fair
Zoe Ravich McNitt
Anna Suddleson
Jill Roberts Freeman
Linda Meadow
Suzette Swalwell
Alyson Fine Marmur
Alyssa Weinberger
•••
EVENT
COORDINATORS
INVITATION
DESIGN
JOURNAL
DESIGN
FTA Events and Marketing
Edyn Elliott Barber
Lissa Mozur Zanville
WE DO support PHASE ONE
A MESSAGE FROM THE
GALA CO-CHAIRS
Dear Friends,
Our theme this year, I DO support PHASE ONE, is a vow recommitting to the fight against
cancer. We honor the past 15 years we have funded research and commit to funding 15 more!
As you all know, Phase One was founded in 1999 after Alberto had successfully completed his
treatment for testicular cancer. Sadly, Kevin was not as fortunate and lost his battle to brain
cancer in 2009. This year, together, we join forces and fight on in Kevin’s memory to fight
cancer.
Indeed, because of the generous support of friends like you, we are doing great
things. Incredible progress is being made in finding safer and more effective treatments.
We thank our wonderful event committee for all their hard work. We thank the board for their
support and trust in following our vision for this evening. We thank the wonderful team of
doctors who dream to find a cure.
This year, our virtual journal has allowed us to donate even more money to treatment and
research. Thank you for your support and understanding that “going virtual” allows for more
dollars funding research as we save on printing a paper journal.
Together we can make a difference in the fight against cancer and we thank you for your
support and for saying “I DID support PHASE ONE”.
Meritt Elliott
Stacy Valner
A MESSAGE FROM
THE BOARD OF DIRECTORS
April 30, 2015
Dear Friends,
On behalf of the Phase One Board of Directors – Welcome to the 15th Annual Gala.
Fifteen! Many of you attending tonight have been to every single Phase One Gala beginning in
2000 at L’Ermitage Beverly Hills. For some of you, this is your first Gala, and you are in for an
extraordinary evening!
One thing we all have in common is that we are here this evening to support early cancer
research and clinical trials.
Since that first Gala, we have raised more than $15 million, funded dozens of clinical trials at the
best medical institutions in Southern California and grown to over 3,000 supporters. This is a
legacy we can ALL be proud of.
We are thrilled that PHASE ONE co-founder Stacy Valner and board member Meritt Elliott are
chairing tonight’s event. Along with their superb and dedicated committee, Meritt and Stacy
have done an outstanding job in creating another one-of-a-kind evening.
The theme for tonight -- I DO – is a pledge for recommitment. A recommitment to PHASE ONE.
A recommitment to those we have lost. A recommitment to those we love who are fighting
cancer. A recommitment to finding a cure for cancer.
The PHASE ONE Board is proud to lead in this recommitment. We have accelerated our efforts
to advance research and therapies for the treatment of cancer by deploying the funds we have
raised through your generous donations. We are visiting all of the major medical facilities in Los
Angeles, meeting with new investigators. This year, we are funding the exciting ovarian cancer
research of Dr. Sanaz Memarzadeh at the UCLA Broad Stem Cell Center. Tonight, guests at
the Gala are able to add their own individual support, via smartphones, to her important work.
Phase One is growing – and growing stronger. This year we welcomed Edward Woods to our
board.
Thank you for joining our quest.
We are redesigning our website
(www.phaseonefoundation.org) and adding wonderful new programs in support of our mission.
Join our mailing list ([email protected]) to learn more.
None of this would be possible without you. Thank you for all you DO to support PHASE ONE!
MARINA COHN
2015 Chair, Board of Directors
A MESSAGE FROM THE FOUNDERS
Dear Friends,
As many of you know, a little over sixteen years ago, my mother and I were diagnosed with very
different types of cancer. Unfortunately for my mother, at the age of 58 and in the epitome of
health, she had a type of cancer where little was known, and she was given a year to live.
Nine days later, I was also diagnosed with cancer. Even though my cancer had pretty much
spread throughout my body, a lot was known about the type of cancer I had and my odds of
survival were more optimistic. After six months of intensive chemotherapy treatments and
multiple surgeries, I was told I was “cancer free.” Just a few days later, my mother passed away.
Both my mother and I were treated by some of the best doctors and medical facilities that
Southern California has to offer. The primary difference between our illnesses was the
knowledge or lack of that existed regarding each one of our cancers.
Therefore, fifteen years ago, Stacy and I became determined to make it our mission to raise
funds for all types of cancer research. Our hope was that no one should be as unfortunate as
my mother was, and that every cancer patient be provided with a sense of hope. A small group
of friends joined with us and Phase One was born. Today, this group of people has grown and
evolved into a large and diverse one representing all walks of life in our city. I am very proud
and thankful for their commitment and leadership. In the last fifteen years, we have funded
millions of dollars for cancer research at every major medical center and research facility in our
greater Los Angeles community as well as at various other national institutions.
Incredible progress is being made on a daily basis in finding safer and more effective
treatments. We are certain that one day cancer will be controlled and ultimately cured in our
lifetimes and Phase One is determined to stay in the forefront of this quest.
We thank you for sharing our vision and for your support.
All my best,
Alberto Valner
WHO WE ARE
BOARD OF DIRECTORS
Marina Cohn
Chairperson
Diane V. Allen
Holly Baril
Royce Bergman
Jordan R. Bernstein
Leanna Creel
Emily Current
Carly de Castro
Meritt Elliott
Mark Freeman
Cecily Jackson-Zapata
Angela Kay
Janet Lonner
Alyson Fine Marmur
Zoe Ravich McNitt
Bradley Meadow
Cary Meadow
Azita Mosbat
Mieke Neumann
Kelly Newman
Tia Palermo*
Missy Polson
Steven Romick
Stephanie Sandler
Alberto Valner
Edward Woods
*(1959-2012)
Lissa Mozur Zanville
Executive Director
• • •
MEDICAL ADVISORY BOARD
Robert Figlin, MD
Chairperson
Cedars-Sinai Medical Center
Stephen J. Forman, MD
Heinz-Josef Lenz, MD
City of Hope
USC/Norris Cancer Center
Philip H. Koeffler, MD
Frank L. Meyskens, Jr., MD
UC Irvine Medical Center/
Chao Family Comprehensive Cancer Center
• • •
256 26th Street ∙ Suite 201 ∙ Santa Monica ∙ California ∙ 90402
310.458.7715 phone ∙ 310.393.6051 fax ∙ www.phaseonefoundation.org ∙ [email protected]
@PhaseOneLA
Facebook • Twitter • Instagram
WHAT WE DO
PHASE ONE is a non-profit organization dedicated to supporting Phase I clinical research and
treatment programs for patients with cancer. The group was founded in 1999 by Stacy and
Alberto Valner, with a small group of friends, all couples with young children. Each one of these
individuals had been affected by a diagnosis of cancer in themselves or in a close family
member.
Once a new idea or novel drug is identified in the laboratory, the FDA requires three levels of
clinical testing prior to the approval of that drug for widespread use. These studies are usually
referred to as trials in Phase I, II, or III. The focus of a Phase I trial is to determine the
appropriate dose and schedule of a given drug and its side effects. Patients enrolled usually
have advanced cancers, which have progressed through standard therapy or for which standard
therapy does not exist. Sometimes these patients have been through "everything" and still
function extremely well. The Phase II trial applies the Phase I information on dose and schedule
and tries to get a hint of efficacy. The Phase III trial is the final set of studies and usually
involves hundreds, if not thousands of patients worldwide. Clinical trials are the only way to
understand the best and safest therapies available to patients with any disease.
With your support PHASE ONE hopes that its efforts to fund Phase I trials and research will
help in the fight against cancer, by finding treatments that will transform what might be a
terminal illness into one where patients can live a full and productive life. PHASE ONE is
determined to:
●
●
●
●
●
●
Offer hope to the patient today that has been told there is nothing left.
Allow patients in our community the access to whatever types of therapy may be
available around the world.
Make the time a patient goes through treatment easier by improving patient care.
Support research that takes advantage of the vast amount of new information about
what causes cancers.
Lay the groundwork for larger scale multi-center research that can set new standards of
oncology care.
Make sure that those diagnosed with cancer in the future will have even safer and more
effective treatments to live long lives with their disease too.
Since 1999, PHASE ONE has raised more than $15 million in support of these trials and
programs at some of the most prestigious organizations in Southern California including Samuel
Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, City of Hope, UCLA
Jonsson Comprehensive Cancer Center, USC/Norris Comprehensive Cancer Center, Children’s
Hospital of Los Angeles and the Premiere Oncology Foundation Lung Cancer Initiative.
WHAT WE SUPPORT
Dedicated to ensuring that the Southern California community has access to the most promising
novel therapies available for those afflicted with cancer, PHASE ONE directed its efforts to
support research that might not be funded by alternative mechanisms.
The studies selected included novel therapies and conventional ones, all having some scientific
question about efficacy, biologic correlates, surrogate markers (radiographic, laboratory, tissue
based or other), or mechanism of action. The findings of these studies will ideally lead to further
research or further independently-funded projects.
2015
Dr. Sanaz Memarzadeh, UCLA Broad Stem Cell Research Center
Grant Amount: $300,000
PHASE ONE is funding a two-year grant, totaling $300,000, in support of Sanaz Memarzadeh’s,
MD, PhD, ovarian cancer research at the UCLA Broad Stem Cell Research Center.
Research suggests that most, if not all, cancers arise from cancer stem cells. Conventional
cancer therapies target rapidly dividing tumor cells, but cancer stem cells have tools to escape
chemotherapy and radiation. At some point, the cancer stem cells begin to self-renew, creating
a new tumor and the cancer begins to grow again.
Ovarian tumors account for about 3% of all malignancies in women, but are responsible for a
disproportionately large number of cancer related deaths. One reason these cancers are
dangerous is that they are detected late. The symptoms of ovarian cancer are often non-specific
and can resemble other common ailments. Currently, there is no definitive screening test for
ovarian cancer; therefore tumors cannot be detected at an early stage.
High grade serous tumors are the most common form of ovarian cancer. Despite being called
“ovarian” cancer, recent work suggests that the majority of these tumors have their origins in the
fallopian tubes. The standard of treatment for high grand serous ovarian cancer is surgical
removal of the tumor followed by chemotherapy. However, most patients with high grade serous
ovarian cancer relapse in one year and many succumb to this illness within five years despite a
complete initial response to therapy. The clinical behavior of high grade serous ovarian cancer
suggests that subsets of these tumor cells have stem cell-like properties and are resistant to
existing therapies. These cells comprise a small fraction of the tumor but are the cancer
initiating cells. In order to eradicate serous cancers, we must first find a way to target the serous
cancer stem cells.
UCLA Broad Stem Cell Research Center member Dr. Sanaz Memarzadeh and her team have
made major progress in isolating this population of serous tumor cells with stem activity (the
cancer stem cells). They believe these cells are responsible for high rates of relapse in ovarian
cancers. More importantly, they have identified and are testing ways of eliminating these tumor
cells by adding drugs to existing standard chemotherapy. They envision a handful of strategies
that can be used to individualize each patient’s care based on tumor analysis in the laboratory.
Their proposed treatments may significantly improve survival of patients. With the generous
support from the PHASE ONE Foundation, Sanaz is moving the first of these therapeutic
strategies forward into clinical trial for treatment of ovarian cancer.
As a practicing clinician it is Sanaz’s experience caring for patients with ovarian and other
gynecological cancers that motivate her to define better, less toxic and more effective
treatments to replace or compliment conventional therapies. Historically, ovarian cancer
research is woefully underfunded; generous philanthropic resources enhance Sanaz’s ability to
pursue innovative and novel ideas that will greatly impact future treatments of this disease.
2014
Dr. Richard Tuli, Cedars-Sinai Medical Center
Pancreatic adenocarcinoma is a devastating disease with the lowest survival rate of any solid
cancer. Gemcitabine chemotherapy and radiotherapy given concurrently remain the mainstay
treatments for patients with locally advanced pancreatic cancer, which cannot be removed by
surgery, but also has not spread to other areas of the body. Both gemcitabine and radiotherapy
kill tumor cells by interfering with their DNA, the genetic blueprint. Veliparib is a poly (ADPribose) polymerase (PARP)1/2 inhibitor; PARP1/2 proteins are also involved in DNA repair.
Studies have shown that inhibiting PARP1/2 activity can significantly enhance the effects of
radiotherapy and chemotherapy in killing tumor cells. Our own laboratory work has shown
excellent synergy between veliparib (a PARP inhibitor), radiotherapy and gemcitabine in killing
pancreatic cancer cells grown in culture, and in prolonging survival in mice with pancreatic
tumors.
Based upon these promising results and with the generous support of the PHASE ONE
Foundation and Diane V. Allen, we are currently enrolling patients in a first-in-human,
investigational clinical study (phase I) to test the safety and efficacy of veliparib in combination
with gemcitabine and radiotherapy in patients with locally advanced pancreatic cancer. Prior to
and during therapy, patient tumor and blood samples will also be tested for levels of different
DNA repair proteins and mutations, such as BRCA1/2. This molecular “signature” will hopefully
serve as a “biomarker” to predict how the patient and tumor are responding to treatment. We
are hopeful that we will be able to select out the subset of favorable patients who respond to this
regimen, and design future studies (phase 2/3) by “personalizing” treatments using PARP1/2
inhibitors.
2013
Dr. Karim Chamie, University of California Los Angeles
Dr. Karim Chamie, with UCLA Urology, is working to combat the rapid increase in recent years
of urothelial cancer by investigating a potentially new treatment method involving a hydrogel
polymer (chemical compound), which is liquid at room temperature, mixed with chemotherapy to
treat this difficult-to-detect and highly reoccurring form of cancer. The polymer-chemotherapy
combination takes on the shape of the cavity of interest (such as a kidney) at body temperature
and has the potential to deliver chemotherapy to the targeted site while minimizing side-effects.
The polymer can also be mixed with a dye that binds to tumor cells to facilitate detection of
tumor cells within a specific organ. Traditionally, what has been most challenging in treating this
type of cancer is the ability to deliver the chemotherapeutic agent at a high concentration level
to the exact tumor site. This new discovery has the potential to overcome the previous
challenge by using the polymer-chemotherapy directly to the targeted site. Dr. Chamie and his
team are optimistic in pursing this study and are grateful to the PHASE ONE Foundation for
supporting these efforts.
Dr. Joseph Riss, University of California Los Angeles
Despite advancement in targeted treatments, metastatic kidney cancer poses a therapeutic
challenge due to its resistance to conventional models of treatment. As long-term survival for
patients with metastatic kidney cancer remains poor, UCLA Urology’s Allan Pantuck, MD and
Arie Belldegrun, MD, along with Joseph Riss, PhD, have been working for years to develop
innovative methods of therapy. With the assistance of critical funding provided by the PHASE
ONE Foundation, this research team developed a kidney cancer vaccine that was recently
approved by the FDA and given to the first patient in February 2013. Even with this grand
milestone, the researchers must now monitor the effectiveness of the vaccine, especially given
the kidney tumor’s resistance to current therapeutics. With the continuous support of the
PHASE ONE Foundation, Dr. Riss and his team will use previously identified indicators to
develop diagnostic tools for monitoring the new treatment and aim to develop a next-generation
vaccine that will combat tumor resistance in metastatic kidney cancer.
Dr. Anna Pawlowska, City of Hope
Ewing’s sarcoma is the second most common primary bone tumor in children and
adolescents. While advances in treatment have increased survival rates for children with
localized disease to nearly 70 percent, fewer than 30 percent of patients who experience
relapse or the spread of their cancer survive. In addition to these grim statistics, there is no
nationally accepted “gold standard” of treatment for patients with advanced Ewing’s
sarcoma. More effective therapies are urgently needed to save the lives of young patients.
City of Hope will be launching a five-year pilot clinical trial to study the effectiveness of a
promising treatment for high-risk patients with advanced Ewing’s sarcoma: whole-body MRIguided radiation therapy followed by autologous hematopoietic cell transplant, with a novel
combination of high-dose chemotherapy. Led by Anna Pawlowska, M.D., Clinical Professor of
Pediatrics, the proposed study will assess whether this therapy is feasible, safe and likely to
increase patient survival rates. A similar approach tested in Germany and Austria increased
children’s survival rate to 70 percent after two years and 56 percent after three years with
minimal toxicity, but this approach has never been tested in the United States.
In a novel approach, guests at the 2013 PHASE ONE Gala DIRECTLY donated $37,000 to help
fund part of this five-year trial by supporting MRI tests for patients not covered by their
insurance and/or support a portion of the salary of a Clinical Research Assistant. This critical
seed funding would help young patients with Ewing’s sarcoma access a promising new therapy
now and start collecting the patient data needed to secure additional public and private funding
for future years of the trial.
2012
Dr. Antoni Ribas, University of California Los Angeles
With the support of the PHASE ONE Foundation we will conduct a phase 1 clinical trial (MART1 F5 TCR Engineered Adoptive Cell Transfer Therapy with CTLA4 Blockade) with the goal of
genetically programming the human immune system to efficiently target cancer cells in patients
with advanced stage melanoma, the deadliest of skin cancers. This clinical trial builds upon the
experience at UCLA over the past 3 years in the use of T cell receptor (TCR) engineered
adoptive cell transfer therapy. This therapy is manufactured in-house and results in the
generation of a large army of immune system cells that are genetically redirected to recognize
and kill melanoma. With this therapy we have noted high initial response rates, but tumors come
back. A major limitation has been a progressive decrease in the antitumor functionality of the
TCR engineered immune cells. The antibody tremelimumab blocks a major negative regulator in
immune cells and will be tested with the goal of maintaining the cancer killing functionality of the
TCR engineered lymphocytes given to patients. This protocol has administrative approval by the
UCLA regulatory committees and it has already been filed and approved by the Food and Drug
Administration.
2011
P.R. Lowenstein, M.D. PhD and Maria G. Castro, PhD
Department of Neurosurgery and Cell and Developmental Biology, The University of
Michigan School of Medicine, Ann Arbor, Michigan
Grant Amount $216,000
Highly malignant brain tumors are uniformly lethal. Patients usually survive less than 2 years
post-diagnosis, with very few still alive 5 years later. In spite of constant developments in
surgery, radiotherapy and chemotherapy a breakthrough for this particularly aggressive cancer
has not been yet discovered. Over the last ten years we have developed a novel approach for
the treatment of brain tumors. Based on an evolutionary and developmental understanding of
the structure and function of the brain immune system, we decided to restitute to the brain those
immune cells normally absent from it, as a potential new approach to treat brain tumors. The
immune cells normally absent from the brain are those in charge of turning on the anti-tumor
immune response. Their absence from the brain helps us explain why normally anti-brain tumor
immune responses are ineffective. By attracting those specific immune cells to the brain and the
brain tumors, we expect them to identify brain tumor antigens and unleash a therapeutically
effective immune attack to eliminate brain tumors. To achieve this we have turned adenoviruses
which normally can cause lung infections and other diseases into therapeutic agents. We have
engineered the viruses to deliver directly to the brain and the brain tumors a protein that will
recruit the missing immune cells to the brain to start a clinically effective immune response. As
our work uses viruses as agents of treatment to induce immune responses, our therapeutic
approach is described as a “combined gene-and immune therapy”. Following more than ten
years of development and experimental testing we are now ready to start clinical trials in
patients suffering from glioblastoma multiforme. With very generous support from the PHASE
ONE Foundation, we are now on the threshold of starting the first ever clinical trials of this new
therapeutic approach for the treatment of deadly highly malignant brain tumors. The proposed
trial, which was approved by the Food and Drug Administration on April 7, 2011 is currently
undergoing the final evaluations by the Institutional Biosafety Committee, and the Institutional
Review Board for Clinical Trials. We expect these evaluations to be finalized within the next few
weeks. Once our trial has cleared all necessary Committee reviews, it will be ready to start.
PHASE ONE has thus provided the green light to move the dreams of two basic scientists into
the challenging arena of clinical trials. As the trial starts enrolling patients we will look forward to
keeping PHASE ONE abreast of all therapeutic developments. We hope, and for the sake of the
patients, we pray, that treating the first patients may represent in Winston Churchill’s prophetic
words, “Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the
end of the beginning.”
2010
Children’s Hospital Los Angeles
In February 2010, PHASE ONE granted $410,000 over two years to fund a Phase I study at
Children’s Hospital Los Angeles. The study, led by Dr. Stuart E. Siegel, is of AC220 for children
with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myeloid leukemia
(AML). This grant will provide an opportunity in getting a second generation FLT3 inhibitor drug
tested in a pediatric population that truly focuses on the concept of FLT3 inhibition in high-risk
ALL and AML patents. The goal of the study is to obtain sufficient laboratory and clinical data to
enable the design of a larger Phase II study. Results from this study would also leverage
funding to support the Phase II part of this project from both the National Cancer Institute, as
well as the pharmaceutical company Ambit that makes the drug.
2009
The Premiere Oncology Foundation Lung Cancer Initiative
Premiere Oncology Foundation, a non-profit dedicated to cancer research, integrative medicine,
patient/family support services and community education, will utilize the grant to support a
comprehensive lung cancer program to include multi-disciplinary research. Lung cancer is the
world’s top cancer killer, claiming more than 1.3 million lives per year, yet few financial
resources have been dedicated to this disease. The Premiere Oncology Foundation Lung
Cancer Initiative focuses on the use of FDA-sanctioned novel treatment regimens in
collaboration with experts in the field of lung cancer detection and treatment. The program will
foster dialog among practitioners caring for lung cancer patients, and provide a means for
seamless interaction with medical and radiation oncologists, thoracic surgeons, radiologists,
pulmonologists and primary care physicians caring for these patients.
Dedicated to whole-patient care and recognized for expediting clinical trials, Premiere’s flagship
cancer center in Santa Monica offers patients the newest cutting-edge treatments, rapid access
to novel, internationally available therapies and integrative medicine all under one roof.
Additionally, Premiere provides services in its Scottsdale, Arizona center and research affiliation
with Pacific Hematology & Oncology Associates in San Diego.
2007–2008
The Samuel Oschin Comprehensive Cancer Institute-Cedars-Sinai Medical Center
Grant Amount: $2,000,000
Internationally renowned cancer researcher Steven Piantadosi, MD, PhD, was named the
inaugural PHASE ONE Foundation Endowed Chair of the Samuel Oschin Comprehensive
Cancer Institute (SOCCI) at Cedars-Sinai Medical Center at a ceremony February 6, 2008.
SOCCI provides cutting edge cancer clinical trials and sub-cellular research, in addition to stateof-the-art patient care. Its research efforts are focused on developing breakthroughs that
translate as efficiently as possible into new methods for the treatment of cancers of the lung,
brain, colon, prostate, pancreas, breast, spine, ovaries, pituitary, thyroid and blood system, plus
melanoma and other cancers.
With this endowment, Dr. Piantadosi will define and direct the activities of the Institute and serve
as a key figure in framing the national debate about cancer, while having a decided impact on
the direction and success of new research.
City of Hope Comprehensive Cancer Center
The City of Hope Division of Medical Oncology and its Department of Clinical and Molecular
Pharmacology, directed by Yun Yen MD, PhD, is the City of Hope Comprehensive Cancer
Center equivalent to a Phase I Solid Tumor Program. In this program is the exciting translation
of molecules from the laboratory to the clinic.
City of Hope will use the PHASE ONE funds to support novel Phase I clinical trials developed in
collaboration with the Department of Clinical and Molecular Pharmacology. These resources
would be utilized to fund novel protocols or existing protocols where additional funds could
translate findings from the laboratory to the clinic. Support for novel “NEW” programs (25–50K/
year for two years) in Clinical and Molecular Pharmacology that can reach the clinic during the
two years of the award, and bring innovation from our laboratories will be the highest priority.
The City of Hope Comprehensive Cancer Center’s Phase I Program has a commitment to the
Developmental Therapeutics and Hematologic Malignancies Programs directed by Yun Yen
MD, PhD, Richard Jove PhD, and Steven Forman MD. City of Hope will establish competitive
awards (25–50K/year for two years) that combine a laboratory and clinical Principal Investigator
that translate laboratory observations into the clinic during this period. Programs in Solid
Tumors and Hematologic Malignancies including lymphomas, in both adults and children would
be included.
2006
Kuk-Wha Lee, M.D. PhD
Dr. Lee is a graduate of the Medical Scientist Training program at Loma Linda University School
of Medicine, obtaining her PhD and MD. Her clinical training is in pediatrics and she was
fellowship trained in Pediatric Endocrinology at the Mattel Children’s Hospital at UCLA. In
training she was the recipient of the prestigious Giannini Foundation Fellowship, SteinOppenheimer Award, and the LWPES Clinical Scholar Award for her research. In addition, she
is the recipient of the UCLA Prostate Cancer SPORE Career Development Award for her
research in cellular and animal models of human prostate cancer. Her laboratory studies the
biological functions of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) and its binding
partners in cancer biology, specifically prostate cancer. Specifically, she studies the molecular
mechanisms by which this molecule enters cells; targets specific areas within cancer cells (e.g.
the nucleus and mitochondria); and initiates the programmed cell death cascade.
Unique assays in their laboratory have been developed to study serum levels of these
molecules and also have developed unique transgenic and knockout mouse models of human
disease. Based on preliminary work published from their laboratory the plan is to initiate a
Phase I trial of IGFBP-3 in men with prostate cancer in the near future.
2005
Karen Reckamp, M.D.—A Phase 1 Trial of Vaccine Therapy with Lung Cancer
With her mentor, Steven Dubinett, M.D., Director of the UCLA Lung Cancer Program, Dr.
Redcamp’s efforts are in the immunologic treatment of lung cancer through novel genetic-based
immunologic stimulation. Her proposal is for a Phase I Clinical Trial of the intratumoral
administration of an immune stimulant called a chemokine to induce an immune response that
could yield immunity to this cancer.
2004
Dr. Arie Belldegrun and Dr. Alan Pantuck
UCLA Department of Urology Specializing in New Treatments for Kidney and other
genitourinary cancers, particularly vaccine therapies directed against newly identified targets.
Dr. Heinz-Josef Lenz and Dr. Daniel Vallboehmer
USC/Norris Comprehensive Cancer Center Specialists in Gastro-Intestinal Malignancy
searching for molecular markers to predict prognosis and response to therapy.
Dr. Charles Sawyers and Dr. Ingo Mellinghoff
UCLA Jonsson Comprehensive Cancer Center Hematology/Oncology Translational Scientists
working on molecular mechanisms that underlie the development and spread of cancer.
Dr. David Agus and Dr. Mitchell Gross
Cedars-Sinai Prostate Cancer Program looking at innovative treatments for prostate cancer and
using information technology systems to identify molecular markers for response to therapy.
2003
Dr. Lee Rosen—Cancer Institute Medical Group
In 2003, Dr. Lee Rosen conducted a Phase I study of a medication that could theoretically shut
down the development of new blood vessels from which tumors grow and possibly spread.
Using a series of radiographic assessments including CT/MRI/Bone scans, etc. as well as
conventional scans such as CT/MRI, Dr. Rosen and his colleagues at the Cancer Institute
Medical Group, examined the response of their patients to this new medication and to what
degree. He also found the use of PET scans, which look at changes in tumor metabolic activity
rather than size, is very effective, PHASE ONE has been sponsoring a trial which will look at
whether a combination of PET/CT scans can aid in the assessment of the drug’s efficacy more
quickly than conventional CT scanning alone.
2002
Dr. Sven de Vos, Dr. Christos Emmanouilides, Dr. William H. McBride and
Dr. Jonathan W. Said—Jonsson Comprehensive Cancer Center
PHASE ONE sponsored an Indisciplinary Grant to study the use of the Proteasome Inhibitor
PS-341 in the treatment of refractory diffuse large B-cell lymphomas in terms of clinical efficacy,
mechanisms of resistance and new models of combination therapy. The study was conducted
by principal investigator, Sven de Vos, M.D., and co-investigators, Christos Emmanouilides,
M.D., William H. McBride, M.D. and Jonathan W. Said, M.D. at the Jonsson Comprehensive
Cancer Center.
2001
Dr. Carolyn Britten—Jonsson Comprehensive Cancer Center
PHASE ONE sponsored the recruitment of a full-time clinical research physician for a full year.
Highly respected oncologist, Dr. Carolyn Britten, joined the faculty of the Jonsson
Comprehensive Cancer Center in early 2001 and PHASE ONE funded her research for one
year. Dr. Britten is involved in four promising Phase I trials testing new and unique therapeutic
strategies in signal transduction and angiogenesis
A MESSAGE FROM OUR
April 30, 2015
Dear Friends,
The Phase One Medical Advisory Board wishes to thank the Board of Directors of Phase One
for its vision in supporting the next generation of cancer scientists. The support of investigators
whose goal is the translation of discoveries to find better, safer, and more effective treatments
for patients with cancer will form the lasting legacy of the Phase One Foundation.
This evening as we celebrate with laughter, entertainment, and fine food, we salute the tireless
efforts of this young and spirited organization. Since 1999, Phase One has raised over $15
million for cancer research, funded more than a dozen research programs, and equally as
important has created greater awareness in our community about the importance of funding
clinical trials and investigative studies.
All of us on the Medical Advisory Board are very proud of achievements like this. But we are
also always aware of how much more has to be accomplished before we can say, “We are
indeed curing cancer.”
Because of the generosity of all of you with us tonight, the task is made easier. Thank you for
giving us the opportunity and for your all-important support of Phase One.
Sincerely,
Robert A. Figlin, MD., FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director
Samuel Oschin Comprehensive Cancer Institute
Robert Figlin, M.D. F.A.C.P.
Robert Figlin, M.D. F.A.C.P. is the Associate Director of the Academic Development Program
and Director of the Division of Hematology/Oncology at Cedars-Sinai’s Samuel Oschin
Comprehensive Cancer Institute. He is board-certified in both medical oncology and internal
medicine. Dr. Figlin previously served as Professor and Chair of the Department of Medical
Oncology and Therapeutic Research at City of Hope. He also was affiliated with the Jonsson
Comprehensive Cancer Center at the University of California, Los Angeles (UCLA) for more
than 20 years, where he held a number of leadership positions in the areas of urologic cancer,
hematology/oncology and thoracic oncology.
Dr. Figlin is a prolific researcher known for advancing urologic and lung cancer therapies. His
expertise has resulted in the development of novel anti-cancer drugs that have led to improved
outcomes for patients. Dr. Figlin has written more than 300 peer-reviewed publications,
authored several books on kidney cancer and published more than 60 book chapters on new
approaches to cancer treatment. He is a fellow of the American College of Physicians and the
International Society for Biologic Therapy as well as a member of the American Society of
Clinical Oncology, the American Association for Cancer Research, the National Comprehensive
Cancer Center Network and the American Urological Association. Dr. Figlin earned his
bachelor’s degree in chemistry from Temple University where he also earned a graduate degree
in organic chemistry. He earned his medical degree from the Medical College of Pennsylvania.
Dr. Figlin served his internship and residency at Cedars-Sinai Medical Center where he was
Chief Medical Resident and completed a fellowship in hematology/oncology at UCLA.
Stephen J. Forman, M.D.
Dr. Stephen Forman has been Chair, Division of Hematology and Hematopoietic Cell
Transplantation, City of Hope National Medical Center and Program Director, Hematologic
Neoplasia, City of Hope Comprehensive Cancer Center since 1987. He first joined City of Hope
in 1979 after completing a fellowship there. He did his undergraduate studies at St. John’s
College, Annapolis, Maryland and attended medical school at the University of Southern
California In addition to serving on the Phase One Medical Advisory Board, he is a member of
the Scientific Advisory Board for the Cure for Lymphoma Foundation, a member of the Scientific
Subcommittee of Transplant Biology for The American Society of Hematology, Chairman of the
Marrow and Stem Cell Committee for the Southwest Oncology Group, and a member of the
Gene Therapy Advisory Council, City of Hope and Beckman Research Institute.
Philip H. Koeffler, M.D.
Dr. Philip Koeffler is a Professor of Medicine at UCLA School of Medicine and is Director of the
Division of Hematology/Oncology at Cedars-Sinai Medical Center. He did his undergraduate
training at the University of Wisconsin, Madison and then attended Baylor College of Medicine
for Medical School Training. He completed his internship and residency at the University of
Southern California, and his fellowship in Hematology/Oncology at UCLA. He went through the
professorial ranks from Assistant Professor to Full Professor at UCLA from 1978 to 1986, and in
1992, he moved his laboratory to a large research area at Cedars-Sinai Medical Center. He has
over 600 peer-reviewed scientific articles published or in press and over 75 chapters in medical
scientific books. Dr. Koeffler uses cellular and molecular biology to ask cancer-related
questions. He has large tissue banks for many different cancers including brain, breast, lung
and leukemias and lymphomas. He has well over 100 different cancer cell lines frozen viably
and at any one time perhaps 30 of these cell lines are growing in the laboratory. In addition, he
frequently uses mice (nude, transgenic, and deletional). Some of his major accomplishments
include: being the first lab to identify p53 to be mutated in human cancer; being one of three
labs to identify p53 as a transcription factor; developing one of the first human myeloid leukemia
cell lines (KG-1) which has over the years has become a model to study leukemia (these cells
were used to clone, for the first time, the alpha interferon gene and to make the CD34 antibody
which has been used to purify hematopoietic stem cells); being first to develop a cell line (KS-1)
infected with Karposi’s Sarcoma associated virus (HHV-8), but not infected with either Epstein
Barr Virus or human immunodeficiency virus; being first to clone cyclin A1, a protein involved in
cell cycle progression and performing experiments to understand the protein’s biology; being
first to clone and study transferrin-2 and receiving a patent on various aspects of this protein
which is important in iron metabolism, and if mutated, causes hemachromatosis; being first to
clone a myeloid transcription factor known as C/EBP, a protein critical for myeloid (white) cell
development (Dr. Koeffler’s lab was one of two labs to first identify the genetic abnormality in
patients with “Specific Granule Deficiency” disease – germline mutation of C/EBP and one of
two labs first to identify mutations in C/EBP in acute myelogenous leukemia. He also noted that
the gene was silenced in a number of other cancer subtypes, a discovery that lends itself to
become a therapeutic target).
Heinz- Josef Lenz, M.D.
Heinz-Josef Lenz, M.D., is a Professor of Medicine and Professor of Preventive Medicine in the
Division of Medical Oncology at the Keck School of Medicine at the University of Southern
California (USC). He is Co-director of both the Colorectal Center and the Gastrointestinal (GI)
Oncology Program, as well as is Scientific Director of the Cancer Genetics Unit at USC/Norris
Comprehensive Cancer Center in Los Angeles. Dr. Lenz received his medical degree from
Johannes-Gutenberg University in Mainz, Germany, in 1985. He completed a residency in
hematology and oncology at the University Hospital Tübingen in Germany, a clerkship in
oncology at George Washington University Medical Center in Washington, D.C., and a clerkship
in hematology at Beth Israel Hospital of Harvard Medical School in Boston, Mass. He served
subsequent fellowships in biochemistry and molecular biology at the Norris Comprehensive
Cancer Center. An active researcher, Dr. Lenz focuses on topics including the regulation of
gene expression involved in drug resistance, patients at high risk of developing colorectal
cancer, determination of carcinogenesis, and methods of early detection and better surveillance
of these cancers. He is a member of several professional societies such as the American
Association for Cancer Research, American Gastroenterological Association, and National
Society of Genetic Counselors. He also serves on the national advisory board of a number of
professional organizations. A Fellow of the American College of Physicians, Dr. Lenz is the
author of numerous peer-reviewed publications and invited papers, reviews and editorials. In
addition to having a National Cancer Institute-funded laboratory, he is a recipient of the
American Society of Clinical Oncology (ASCO) Young Investigator Award, ASCO Career
Development Award, and the STOP CANCER organization’s Career Development Award. He
has been listed in the BestDoctors.com database since 2003.
Frank L. Meyskens, Jr., M.D., F.A.C.P.
Dr. Frank Meyskens is Professor of Medicine and Biological Chemistry, Director of the Chao
Family Comprehensive Cancer Center, and Senior Associate/Dean of Health Sciences for the
College of Health Science at UC Irvine. He was originally recruited to UC Irvine in 1989 as
Professor of Medicine and Biological Chemistry and to serve as Medical Director of Oncology
Services and Chief of Hematology/Oncology with the mandate to develop a Cancer Center. He
received his M.D. and interned at the University of California, San Francisco, and completed his
Medical Oncology training at the National Institutes of Health, during which time he conducted
molecular biology investigations in the Laboratory of Tumor Cell Biology. Since 1977, he has
been continuously funded by the National Institutes of Health. Prior to UCI, Dr. Meyskens was at
the Arizona Cancer Center at the University of Arizona where he served as Associate Director
of Cancer Prevention and Control, from 1984 to 1989, and established one of the most
successful Cancer Prevention Research Programs in the world. While at Arizona, he was
Principal Investigator of the Vitamin A and Chemoprevention Program Project (PO1 CA 27502)
and the PO1 CA41108 Program Project for the study of colon cancer and prevention. He has
established a similar chemopreventive effort at UCI and is conducting phase I, II, III and IV
chemopreventive trials supported by the NCI and NIH. His current major efforts also include
accrual to a phase IIb trial of Bowman-Birk Inhibitor in oral leukoplakia, a phase IIb/III cohort of
patients at risk for colon polyps treated with DFMO plus sulindac versus placebo, and a unique
natural history, epidemiology and chemoprevention study of patients at high risk of prostate
cancer based on familial background. All studies have extensive translational components and
are funded by the National Cancer Institute. Additionally, for over 25 years he has conducted
active clinical and laboratory research into the cellular and molecular mechanisms of
transformation of human melanocyte and melanoma cells and he is recognized as one of the
premier clinical and experimental oncologists concerned with melanoma.
CANCER RESOURCES
Phase One Foundation
(310) 458-7715
www.phaseonefoundation.org
A Fresh Chapter
www.afreshchapter.com
[email protected]
Tia’s Hope
www.tiashope.org
[email protected]
American Cancer Society
(800) 227-2345
www.cancer.org
John Wayne Cancer Institute
at Saint John’s Hospital and Health Center
(800) 262-6259
www.jwci.org
Cedars-Sinai
Samuel Oschin Comprehensive
Cancer Institute
(310) 423-8030
www.cedars-sinai.edu
UCLA Jonsson
Comprehensive Cancer Center
(310) 825-5268
www.cancer.ucla.edu
Chai Lifeline
(877) 242-4543
www.chailifeline.org
USC/Norris
Comprehensive Cancer Center
and Hospital
(800) 872-2273
(323) 865-3000
http://uscnorriscancer.usc.edu
Children’s Hospital Los Angeles
Children’s Center
for Cancer & Blood Diseases
(323) 669-2121
www.chla.org
Vital Options International:
“The Group Room”
(818) 508-5657
www.vitaloptions.org
City of Hope
(626) 359-8111
www.cityofhope.org
Pancreatic Cancer Action Network
(PanCAN)
(310) 791-5214 or (877) 272-6226
www.pancan.org
Cancer Support Community
Benjamin Center
(formerly The Wellness Community)
(310) 314-2555
www.cancersupportcommunitybenjamincenter.org
• • •
15 YEARS…15 GALAS
Visit our Facebook Page (PhaseOneLA) and website (phaseonefoundation.org)
for photos from past events
2000
2008
L’Ermitage Beverly Hills
Chair
Stacy Valner
Beverly Wilshire Hotel
Co-Chairs
Laurie McCartney
Missy Polson
Julie Sachse
Anna Suddleson
2001
Cicada Downtown Los Angeles
Chair
Diana Nathanson
2009
Phase One “Non-Event”
2002
Four Seasons Beverly Hills
Chair
Janet Lonner
2003
Four Seasons Beverly Hills
Chair
Marci O. Foster
2004
Beverly Hills Hotel
Co-Chairs
Dana Asher
Lisa Gores
2005
Hangar 8 at the Santa Monica Airport
Co-Chairs
Nancy Newberg
Tia Palermo Ravich
2006
Regent Beverly Wilshire Hotel
Co-Chairs
Dana Asher
Lisa Gores
2007
Beverly Wilshire Four Seasons Hotel
Co-Chairs
Laurie McCartney
Erica Wertheim Zohar
2010
SLS Hotel & The Bazaar
Co-Chairs
Tia Palermo
Missy Polson
2011
SLS Hotel & The Bazaar
Chair
Tema Schrage
2012
Montage Beverly Hills & Bouchon Bistro
Co-Chairs
Marina Cohn
Mieke Neumann
2013
Co-Chairs
Marina Cohn
Mieke Neumann
2014
Co-Chairs
Angela Kay
Stephanie Sandler
2015
Wallis Annenberg Center for the Performing Arts
Co-Chairs
Meritt Elliott
Stacy Valner
HEARTFELT THANKS
Albert & Holly Baril
Kaye Popofsky & Jeremy Kramer
Camille Bergher
Mira & Brian Lee
Royce & Ashleigh Bergman
Jody & David Lippman
Bari & Fred Bernstein
Lonner & Kurtzman Families
Emily & Jordan Bernstein
Alyson & Ori Marmur
Dorian Bilak
Katie McGrath & JJ Abrams
Bernard & Judy Briskin
Marla & Brett Messing
Milken Family Foundation
Cherokee Global Brands
Kathryn & Sam Naficy
Marina & Adam Cohn
Mieke & Spencer Neumann
Carly & Alejandro de Castro
Nancy & Bruce Newberg
Disney Company
The Newman Foundation
Diane & Roger Duhl
Kathy & Joe Pretlow
Jill Roberts & Mark Freeman
The Ravich Family
Maryann & Irwin Gold
Eden & Steven Romick
Ron & Betty Goldie
Ellen & Richard Sandler
Elizabeth Goldhirsh
Stephanie & Nicholas Sandler
The Goldhirsh-Yellin Foundation
Amie & Asif Satchu
Laurie & Christopher Harbert
Reagan Silber
Martha & David Ho
Topson Downs
Martha & Bruce Karsh
Stacy & Alberto Valner
The Kayne Foundation
Edward & January Woods
Our sincere gratitude to those whose generous contributions reached us after press time
Thank you
Meritt & Stacy
•••
PHASE ONE
BOARD OF DIRECTORS
To our Dedicated Team
The Dinner Committee
Holly Baril
Emily Bernstein
Leslie Birnbaum
Marina Cohn
Leanna Creel
Emily Current
Natalie Fair
Jill Roberts Freeman
Alyson Fine Marmur
Marci Foster
Maryann Gold
Angela Kay
Brooke Lande
Dana Levine
Janet Lonner
Zoe Ravich McNitt
Linda Meadow
Mieke Neumann
Elissa Phillips
Missy Polson
Kimberly Reed
Stephanie Sandler
Tema Schrage
Debra Silverstein
Anna Suddleson
Suzette Swalwell
Alyssa Weinberger
We thank you for all your hard work, inviting all your friends,
attending meetings, and inspiring us with creative ideas
to make the Gala a success.
And special thanks to
Meg Noyes
Ariella Masjedi
Lindsey Bledsoe
for making the Mystery Gifts look beautiful!
Meritt & Stacy
Edyn Elliott Barber
Thank you for creating our logo and invitations!
•••
FUN FACT
Edyn gave birth the night the invitations were complete!
2 jobs well done!!
Thank you!!!
•••
Meritt and Stacy
Debbie and Leslie
Mystery Gift Fearless Leaders
We thank you helping us raise
additional funds tonight
to fight cancer and
ensuring that it is FUN!
•••
Meritt and Stacy
Maryann & Suzette
Thank you for making our vision
become a reality tonight at the
Wallis Annenberg Center
Thank you
Leanna Creel and Meritt Elliott
and to your team
Aaron Anderson
Evan Barthleman
Miranda Campolo
Maureen Flannigan
Ross Grant
Rinat Greenberg
Tracy Hof
Mandy Moore
Heather Petrone
Noah Philipps-Edwards
Heather Reid
for another incredible video and
for showing us – so beautifully – that
YOU DO support PHASE ONE!
•••
We especially want to thank
Ashley Walton
for sharing your story with us
and in loving memory of
Kristine Reid
•••
PHASE ONE BOARD OF DIRECTORS
Marci and Greg Foster
•••
Thank you for never saying
“I CAN’T” to Phase One!
Your kindness and generosity to
Phase One is never ending.
Every time we see a Phase One Hat
in the community
we will think of you!!!
•••
Stacy and Alberto
Meritt and John
Lissa,
The words
“YOU DO” support Phase One
have never been more true.
Patience, dedication, understanding,
referee and support
are all words that describe all you do for us!
Thank you for all you “do” always.
Stacy and Meritt
Franci
For all your hard work
we are GRATEFUL!
• • •
Meritt & Stacy
Thank you so much
for capturing the special moments
of our event.
CURE
• • •
and are proud to stand with them
in the fight against cancer
and the hope for a cure!
Judy & Bernie Briskin
Mummy,
We are so proud of everything you do
to help find a cure for cancer.
You’re the best Mummy on the planet
and we love you so much!
Love,
David, Charles & Aerin
xoxoxo
WE DO
•••
The Kramer Family
Kaye, Jeremy, Maxime, Jules and Oscar
Marina,
Thank you for your tireless dedication to
PHASE ONE!
Love,
Mieke and Spencer
We are proud to support Phase One
and congratulate our dear friend
Stacy
for her dedication to this important cause.
With love,
Nancy and Bruce Newberg
We are grateful to be able
to support an organization
which funds some of the
best and brightest
medical researchers
on the cutting edge of
cancer discoveries.
•••
January and Eddie Woods
LIFESAVER
• • •
Phase One.
Katie McGrath & J.J. Abrams
Family Foundation
...
We salute Phase One
and its amazing accomplishments.
•••
Susan Vann Kurtzman & Rick Kurtzman
Sharon Klein & Howard Kurtzman
WE DO
commit ourselves in continuing to be a part
in making a difference until a cure is found!
WE DO
celebrate everyone who works so hard for
Phase One!
•••
Janet & David Lonner
To my Queen
You are the keeper of all things beautiful in our family.
Your dedication to art, life, and love inspires us every day.
We are truly thankful for your boundless compassion
and infinite wisdom.
Love,
Dada, Lyric, and Wolfe
Mommy,
15 years hasn't aged PHASE ONE (or you) one bit!
Congratulations on an amazing event.
We love and are beyond proud of you.
All of our love
Lucy, Sophia, Harry, Niki
DADDY
YOU ARE OUR HERO
YOU MAKE OUR DREAMS COME TRUE
STACY
SOPHIA NIKI HARRISON LUCY
2015
Three years without Tia is three years too many.
We miss you every day.
Stacy & Alberto
of
In loving memory of
Kevin Carlberg
The Board of Phase One
In memory of
Marilyn Silverstein
Phase One Board of Directors
HEALER
• • •
Thank you to all
who have helped us
follow the science and funded a
Phase One clinical trial.
Together we will cure cancer
one therapy at a time!
Love,
Holly, Albert,
Alexandra & Graydon Baril
I DO
Support and Applaud all the Achievements
Phase One Foundation
Has Made Over the Past 15 Years
Here's to the Next 15 Years and
Finding Success in the Researchers and Trials
We Fund
• • •
Royce & Ashleigh & Greyson
and Emily Bergman
Amanda Brown &
Justin Chang
are proud to support
Phase One
In Loving Memory of
Meg Mazursky
•••
Carly & Alejandro de Castro
F*$% CANCER
JILL ROBERTS-FREEMAN AND MARK FREEMAN
Cancer is a beast
and we support the efforts of
Phase One and all those that work
to beat that horrible beast
into submission!
• • •
Betty and Ron Goldie
You’re still the One!
xo
The Harbert Family
We are so proud to be part of the
PHASE ONE family.
Thank you to
MERITT & STACY
For putting together
this year’s amazing event
•••
ALYSON & ORI MARMUR
Stacy,
Your passion & commitment to Phase One
have been an inspiration to us all.
Thank you for all that you do.
Love,
Cary, Linda, Sarah, Eve & Ruby
Thank you
Phase One,
for all the great work you do!!
•••
The Messing Family
We are proud to support the
extraordinary work of
Phase One.
We’re grateful to the Board and Event Committee
for all their hard work and dedication.
With love,
Sabina and David Nathanson
The Newman Foundation
It is a privilege to honor
the outstanding work of Phase One
and to congratulate its Chair,
Marina Cohn,
our dear friend,
Stephanie Sandler,
And the rest of the Board of Directors.
• • •
Ellen, Richard & Tracy Sandler
We are proud to support Phase One.
Here's to finding a cure.
Stephanie and Nicholas Sandler
Phase One is
Fighting and Winning the Good Fight!
Congratulations to you all and to our beloved
Mieke
The Schechter Family
Congrats to Phase One
for all the good work
you do.
Reagan Silber
Tia
You are always in our hearts
With all of our love,
•••
Orna and Keenan Wolens
WELLNESS
• • •
Congratulations
•••
Lynn & Les Bider
Thank you!
In loving memory of
Kelly Romick
•••
Kate and Jeff Colin
In appreciation for the years of research
which has led to the diagnosis and recovery
of my daughter
Eileen Coskey Fracchia
and to
David and Janet Lonner
for their dedication to the work of Phase One.
•••
Rhea Coskey
The Davidow Charitable Fund
proudly supports Phase One
Marci & Greg Foster
We treasure our friendship,
and proudly admire your devotion to
Phase One –
a reflection of your
generosity and compassion
With love,
Marci & Jeff Dinkin
Thank you for
supportingPhase One
Marina
Your courage, strength and vision
inspire us all.
May you continue
your great work for
PHASE ONE
With love,
Cynthia & Ralph Finerman
Pam & Stan Maron
Thank you for supporting PHASE ONE
Fleury Estate Winey
950 galleron rd.
rutherford, ca
p. 707.967.8333
[email protected]
We salute the efforts of
PHASE ONE
to find the cure
We congratulate
Mark and Jill Freeman
for their efforts
• • •
JUDY AND LARRY J. FREEMAN
Congratulations to
Phase One
and the
Meadow/Valner Families
on creating a lasting legacy of
compassion and research!
•••
Lori, Simon &
Charlotte Furie
Stacy and Alberto
Thank you for championing such a great cause and
bettering the lives of so many.
•••
Sandy and Jeff Hudson
Congratulations
PHASE ONE
on an incredible 15 years.
Here’s to the next phase of the journey…
I DO!
•••
Angela Kay & Michael Richards
The Kay Family says
I DO
to Phase One!
Congratulations to
Stacy, Meritt, Angela
and everyone at Phase One
for their hard work and dedication.
Cindy and Jerry Kay
Courtney and Andrew Kirsh
Michael Richards
Thank you
Richard & Kathy Leventhal
•••
Thank you
Marina Cohn
and everybody at
Phase One
for your hard work and extreme dedication
to this very important cause!
•••
Andrea and Jason Lublin
Stacy and Alberto –
For the past 15 years, your dedication to cancer research
has been an inspiration to all of us.
We are so proud of you both – and proud to say
WE DO support PHASE ONE!
•••
Mary & Steve
the important work of
PHASE ONE
and congratulate
Marina Cohn
for her amazing efforts!
Sarah and Jeremy Milken
such a great cause.
Thank you Eddie Woods
for the introduction.
~
John and Audrey
Stacy and Meritt,
Congratulations on a
fabulous and successful event!
And thank you to our incredible
friends and family
who have supported Phase One!
•••
The Polson Family
Missy, Glen, Scotty, Brett and Matty
Special thank you to
Leah Radow
an incredible, caring student at
Paul Revere Middle School’s
Eco Homeroom.
She organized a bake sale, with the
“Go Green” club and sponsor Ms. Chen,
to benefit Phase One and cancer research!
The future is in great hands with
young people like you!
•••
Congratulations to all our friends
at PHASE ONE for all of their
remarkable work.
•••
Sheri & Marc Rapaport
Thank you to Phase One
for your continued progress
in finding a cure for cancer.
Patty and Michael Rosenfeld
We are pleased to support
Phase One.
Harriet & Eric Rothfeld
Stacy and Alberto –
Look what you started!
15 years of giving
15 years of research
15 years of advancement
in the war against cancer!
We’re so proud!
With love,
Frankie and Barry Sholem
Cece and Bill Feiler
Heidi and David Haddad
PHASE ONE
and the tireless efforts
of so many in search of a cure
•••
Carolyn and John Tipton
We honor Holly and Albert
for all of their charitable work!
Our love,
Stephanie and Leon Vahn
Thank you for your support
BELIEVER
• • •
How wonderful it is that nobody need wait a single moment before
starting to improve the world.
~ Anne Frank ~
Royce You never waste or wait a single moment to
help others. We are proud of your contributions to
Phase One and grateful for all that you do for us.
Lise & Rob Applebaum
We are happy to support the good work of Phase One
···
Gail and George Baril
&
Allie Newman
•••
The Beckerman family
In honor of Kelly.
We continue to fight to find a cure.
Chet and Donna
Congratulations to all our friends who work
so tirelessly on behalf of Phase One.
Lisa and Jordan Bender
IN LOVING MEMORY OF
LINDA BERNSTEIN
and
IN APPRECIATION OF
PHASE ONE
•••
The Bernsteins
Jonathan, Jessica,
Jordan, Emily and Marshall
We congratulate our friends,
Eddie and Jan Woods,
for being involved with Phase One
and the great work they are doing.
...
Much love,
Shelley and Marty Cooper
Dear Mieke and Spence –
We support your support of Phase One.
Love,
Julie and Roger Corman
In recognition of
Stacy and Alberto Valner
for all of their passionate dedication to
PHASE ONE
•••
Jaye and Neal Eigler
Thank you Phase One
With appreciation and gratitude
...
Quinn and Bryan Ezralow
Congratulations to
Marina
for all of her hard work for
Phase One.
•••
Judy and Jerry Felsenthal
Laura Fox and Ben Van de Bunt
are proud to support
the incredible work of
PHASE ONE
Megan, Alexander and the Gaon Family
wish to take this opportunity to thank
the greatest doctors in the world –
Dr. Allen Chan, Dr. Allen Ho,
Dr. Shahrooz Eshaghian and Dr. Bob Leibowitz –
for all they have done for us.
We love you from the bottom of our hearts and
appreciate the impact you have had on our lives.
Thank you for all the love and dedication
you have shown to me and my family.
In memory of Tia Palermo,
and in honor of our many friends
who lead Phase One
with their hard work and commitment,
we are proud to support Phase One.
•••
Priscilla and Jamie Halper
Missy Polson and the entire Phase One team,
We are so proud of and thankful for
your continuous dedication and
involvement with
Phase One!
Love always,
Jen, Andy, Josh, Ryan and Brooke Howard
Private Client Advisors
Congratulates the PHASE ONE Board of Directors
for their exceptional work and commitment to curing cancer
Todd Van Donge, Senior Vice President – HUB International/Private Client Advisors
700 S. Flower Street, Suite 1520, Los Angeles, CA 90017
Direct: 213-996-4006 Mobile: 213-926-7220 Fax: 323-686-5409 License #: 0745713
Email: [email protected]
Marina, Leslie & Roger,
Congratulations on all your hard work!
XO,
Julie Jaffe
Congratulations to Phase One
for everything you do!
•••
Mary and Dan James
Thank you,
Phase One!
We are inspired by your leadership
in support of innovative research.
•••
Meredith and David Kaplan
Stacy...
You're the best !
Love
Susan and Jonathan Krane
We are in support of
Phase One’s dedication
towards fighting cancer.
•••
Best wishes,
Les & Cyndy Lederer
To Stacy and Alberto,
Here's to all the Phases of our lives that we have
shared together.
We love you,
Dana and David Levine
Stacy
Congratulations!
You and your family's commitment
make us proud to be a part of
PHASE ONE
Love,
Laurie, Jack and Ally McCartney
Congrats to Alberto, Stacy and Phase One's many leaders
on the hard work that turned
an idea into a remarkable 15 year run!
We are so proud of you and honored to be a part of
Phase One.
Brad, Jodi and Leo Meadow
•••
The Hirsh - Naftali Family
Congratulations to
Steve Romick
for your important work with Phase One
•••
The Nathan Family
Thank you
PHASE ONE
and our friend
MARINA COHN
For Your efforts
are changing lives
HEDY & BENJAMIN NAZARIAN
Marina,
We love you!
Melanie & Mike
You are never too young to join the fight against cancer
•••
The Newman Foundation is proud to support Phase One
and help build new youth projects
Congratulations to all of our friends
dedicated to making a difference!
•••
Liz and Michael Nyman
Congratulations to Stacy & Alberto
and the whole Phase One Board
on 15 great years!
•••
Love,
Elissa, Rick, Alexis, Spencer & Holden
We are proud to support PHASE ONE
and the important work that you do.
•••
Lyle and Lisi Poncher
Thank you
Marina
for your tireless efforts
in support of cancer research
Tammy & Richard Ratner
Congratulations to Marina & Jordan
on another successful event!
~
Bella & Rafael Shpelfogel
We are proud to support the
great work of PHASE ONE
•••
Jason and Embeth Sloane
and the incredible work they are doing.
Irene and David Smith
Susan Sullivan & Connell Cowan
are proud to say…
WE DO support Phase One
and all the lives it will save.
The Swalwell Family
Congratulations to Phase One
for the wonderful work that you do.
Mary Ann Weisberg & Bryce Perry
We salute Holly and Albert Baril
in their commitment to finding a cure!
•••
With admiration,
Jennifer and Randy Wooster
Mom,
We miss your smile
everyday.
Love,
Nancy & Lissa
Eddie,
If it’s important to you,
it’s important to me.
XX,
Mistech
Thank you to
Phase One
for fighting to eradicate cancer.
•••
A special thank you to
Marina Cohn.
We are so proud of you.
•••
Dayle and Abe Zukor
With love to
Jordan & Emily
Bernstein
The Colmans
TO ALL OUR FRIENDS
WHO HAVE WORKED
FOR
15 YEARS TO MAKE
PHASE ONE
SUCH A SUCCESS
CONGRATULATIONS!!
KEEP UP THE
GREAT WORK!
NANCY & MIKE
EISENSTADT
I believe your spirit
Tia
will comfort and aid
those who need your
care and love.
Mimi Ravich
STATE NARROW FABRICS
Worldwide Manufactures of Elastics
323-232-8881
SPECIAL THANKS
Adidas
AEG Facilities
Akasha Restaurant
Alimento Restaurant
Diane Allen
Wallis Annenberg Center for
Performing Arts
Dana Asher
Katie B. Photography
Bandolier
Edyn Elliott Barber
Holly Baril
Barry’s Bootcamp
Beats by Dr. Dre
Royce Bergman
Emily & Jordan Bernstein
Beauty Undercover
Beyond Yoga
Leslie Birnbaum
Franci Blattner
Lindsey Bledsoe
Boomtown Brewery
Bottega Louie Restaurant
Bouchon Beverly Hills
Calabasas Catering
Cheeky’s Restaurants
Cherokee Global Brands
Church & State Restaurant
Marina Cohn
Comoncy
Coral Tree Café
Leanna Creel
Anne Cronin Photography
Emily Current
Carly de Castro
DryBar
Meritt Elliott
El Encanto
Exsel Inc.
Falcon Spirits
Brian Fleury
Fleury Winery
Flywheel
Marci & Greg Foster
Four Seasons Resort &
Biltmore Hotel
FTA Events & Marketing
Cindy Gold
Gold/Wong Photography
Maryann Gold
Dana Goldberg
Gracias Madre
Gratus
Rinat Greenberg
Healthy Spot
Carolina Herrera
Illume Spa
IMAX Entertainment
Jerry’s Deli
Lee Jossel
Jouer Cosmetics
Juice Served Here
Thomas Keller Restaurant Group
La Dolce Vita
Helmut Lang
Richard Leventhal
Lifespring Bodywork
Locanda del Lago
Ariella Masjedi
Brad Meadow
Milo & Olive Restaurant
Milly & Li Jewelry
Montage Laguna
Moonshadows Restaurant
Neiman Marcus
Bob & Kelly Newman
Meg Noyes
Sylvia Olson
Paige Denim
Elissa Phillips
Porta Via
Pressed Juicery
Micki Puopolo
John Rankin
Jess Ravich
Zoe Ravich McNitt
Red Room
Jill Roberts & Mark Freeman
Lauren & Anton Schiff
Ava Shambam, M.D.
Silk’n Home Skinovations
Debbie & Rob Silverstein
Anne Sisteron Fine Jewelry
SoulCycle
Sprinkles Cupcakes
Staples Center
Henry Stupp
SugarFISH
The Sunset Restaurant
Suzette Swalwell
Tempt
Terrine Restaurant
Thibiant Beverly Hills
Toscana Restaurant
David Truly
23rd Street Jewelry
UCLA Broad Stem Cell Research
Center
Debbie Valner
Stacy Valner
Velvet by Graham & Spencer
Vince.
Elyse Walker
Wally’s Wine and Spirits
Ashley Walton
Claudia Wong
Wood & Vine Restaurant
Edward Woods
Young’s Market
Katy Zanville
Our sincere gratitude to those whose generous contributions reached us after press time
PHASE ONE WALL OF THANKS
Thank you to the nearly 3,000 individuals and businesses that have supported PHASE ONE since
our founding. Because of you, we have raised more than $15 million and funded innovative
cancer therapies and clinical trials throughout southern California.
Abber Abbott Abeger Abramhams
Abramovitch Abrams Abronson Ackerman
Adam Adams Addington Adelson Adelstein Adrien Aghajani Aglubat Aguado Ahmed
Akerblom Akin Al Alaoui Alanis Alano Alderson Aldisert Alhart Ali Alkon Allard
Allen Allen-Segal Allis Allman Palmer Aloni Alper Alpin Altman Alton Ament Ameri
Amster Andelson Anderson Andes Angarella Angel Angeledes Angepat Anka Ansell
Antenucci Anteyles Antin Apel Appel Applebaum Appleby April Aquino Arana
Araujo Arcy Arena-Nicoll Arenson Argenna Argentieri Argo Arkoff Arlen Arlook
Armand Armetta Armstrong Arnold Aronoff Aronowitz Aronzon Arrillaga Arsuaga
Arutt Ashamalla Ashbee Asher Asherson Assor Aten Atkinson Atlas Attanasio
Atwater James Atwood Auerbach Augunas August Austin Babacoff Babbush Bach
Bachner Bachrach Bader Baer Bahr Baker Balas Baldecchi Baldwin Balkin Ball
Ballarini Bandelt Banducci Banos Barad Baradaran Barber Barcy Baren Barger
Baril Barkhoudarian Barkin Barlava Barnhisel Barrile Barron Barta Basch Bass
Bassman Bastien Bateman Bates Weide Batiste Batra Baum Baumgart Baumgarten
Baxter Beach Beardmore Beattie Beck Beckman Bedil Beebower Beeks Beeman
Behar Beitcher Belanger Belfield Bell Beller Belzberg Bender Benedek Benell
Benjamin Benjamin Cohen Bennett Bension Benveniste Benzaken Bercsi Bercu Berg
Berger Bergher Berghoff Bergman Bergsneider Berkett Berkowitz Berkus Berlin
Berman Berman-Masters Bernard Bernardi Bernhard Bernstein Bernt Bertram Best
Bettinsoli Beyda Beyer Bhandari Bider Bieber Biery Bilak Biltz Bindley Binenfeld
Bingham Biren Birnbaum Bitterman Black Blackman Blackmore Blake Blank Blatt
Blatteis Blau Bliese Blitz Bloch Block Blonder Blondman Lax Bloom Bloomfield
Blum Blumenfeld Blumenthal Boesky Bolour Boltor Bomberg Bomes Bond Boone
Boorstin Borden Bordy Boren Borinstein Borman Bornstein Bosse Bosworth Botel
Bottger Botwinick Boucher Bourgeois Bowman Boylan Bradley Brady Braff Brager
Brancato Brander Brandler Brantman Brau Brau Braun Bray Breakstone Bregman
Brende Brendlinger Brener Brenneman Brent Breslauer Bresler Breslin Bresslin
Brewer Bright Brill Briller Brillstein Brindley Brisbin Brisker Briskin Brittan
Brittenham Brock Broder Broffman Broidy Bronson Brookman Brooks Brosnahan
Brotherton Brown Brownstein Bruck Bruckheimer Brufsky Bruggeman Brumer
Bruskoff Brussell Bryan Brylawski Bryson Bub Bubbers Bubser Buc Buch
Buchanan Whipple Buckhantz Buckingham Bucksbaum Burk Burke Burkett Burkle
Burns Bursteen Bushkin Butler Byer Byers Byrd Byron Caan Caffray Cahoon
Callender Calne Cameron Camp Tamakwa Canale Cane Cannava Canny Cano
Cappello Capps Cardoso Carlberg Carlile Carlson Carmack Carmody Carney Carnot
Caron Carrabino Carroll Carter Caruso Case Casemore Casey Cassini Castaneda
Castano Castro Castro-Abeger Cearnal Cedars-Sinai Cerda Chais Chalmers Chalom
Chambers Chamie Champa Chan Chang Chapluk Chasin Chatinsky Cherniak
Chiklis Chin Chiverton Chmara Chmiel Christian Chu Chudd Cicero Cilic City of
Hope Clark Clement Clifford Clippinger Cobb Coden Codikow Cohan Cohen Cohn
Cole Coleman Colin Colleary Collins Colman Combs Conklin Conners-Copeland
Constantiner Content Contreras Cooke Cookler Cooper Coppel Coppersmith Corday
Coren Corman Cornell Corrigan Corso Cort Cortez Corton Corwin Cosgrove
Coskey Costa Cotsen Cottle Counter Cox Coyne Coyne Donnel Craig Cramer
Crandall Crann Crawford Creed Creed Optican Creel Crippen Crofton Cross
Crosson Crown Croxall Crystal Cummins Current Curtis Cuyjet Cycon Daly Damato
Damavandi D'Amour Danelian Daniel Daniels Dano Danpour Danza Dater David
Davidow Davidtz Sloane Davila Davis Dean DeBones de Castro Dedona De Joy De
Kay Del De Leo Delevie Delgado Delone DeLone De Mann Dembo Dempsey Denisi
Dennis De Roy De Santis De Shannon de Shulthess Des Jardins De Turck Deutch
Deutsch Deutschman Dexter Diamond Di Bonaventura Dickerman Dickinson Diemer
Dietz Dietz Lipsett Di Gennaro Dill Diluzio Di Napoli Dinhut Dinkin Di Nome Di Novi
Dinovitz Dishell Dishman Disney Dobkin Dodd Doft Dolgen
Doll Domanski
Donahue Doner Dooley Doran Dorfman Doron Doroshow Dorskind Dorst Doumani
Dowell Downing Dresner Dressler Dreyer Dreyfus Driver Drooks Drori Druker
Drumwright Druyanoff Dubbert Dubchansky Dubin Dubrow Duffy Duhl Du Manoir
Dunkle Dunlap Dunleavy Dunn Du Preez Dupuis Duran Dvorak Ebner Eckmann
Edelman Edmiston Edwards Egerman Eghbali Ehrlich Ehrman Eigler Einstein Eisen
Eisenberg Eisenstadt Eisner Ekstrand Elazar Elazer Elfman Elias Elkin Elliot Elman
Emanuel
Emerson
Emquies
Enenstein
Engel
Engelbrecht
Epstein
Erlanger
Eshaghian Eshaya Esses Evangelatos Evans Evensen Everman Ezer Ezralow
Factor Fair Falls Family Farber Farrell Farris Feder Feffer Feil Feiler Feinberg
Feld Felder Feldman Feldman Bloom Felice Felix Fellman Felsenthal Feltheimer
Feltz Ferber Feuerman Fickman Fields Fifield Figlin Fine Fineman Fine Marmur
Finerman Fine Tenzer Fini Zanuck Fink Finkelstein Finley Firestein Firestone Firring
Fischer Fish Fishbein Fisher Fishman Fitterman Fitzgerald Fitzpatrick Flagel Flagg
Flahie Flamini Flatow Fleck Fleishman Fleiss Flesh Fletcher Flockhart Fogel
Fogelman Fonda Foos Ford Fordyce Foreman Forester Forman Forrest Forster
Jones Forsyth Foss-Brown Foster Fox Fracchia Fradin Fragen Frandzel Frank
Frankel Frankenheimer Franks Frantz Fraser Freedman Freeman Freitag Fremont
Frenkel Freund Frey Friedberg Friedkin Friedlander Friedman Friedstadt Friend
Friendly Fritz Fryman Fuchs Fuller Fullmer Funk Furie Furlong Bercu Furman Furst
Gaba Gadinsky Gagerman Gale Gallagher Galton Galvan Ganiard Ganz Ganzer
Gaon Gappy Garavente Garbutt Garden Gardner Garfin Garland Garner Garrison
Garvey Gary Gasmer Gaspers Gastaldi Gastelum Gathrid Gaughan Bowman Geffen
Geibelson Gelb Gelfand Gelfand Stearns Gelfan Stone Gelfond Geller Geller-Fields
Gellman Gendelman Gerard Gerber Gersh Gershwin Gerson Gertz Ghazinouri
Ghoreichi Ghoreishi Ghyzel Gibbons Gifford Gigliotti Gilderman Gilhuly Gillett Gilman
Gilroy Gimbel Gingold Ginsburg Glantz Glaser Glass Glasser Glazer Gleiberman
Glick Glist Glover Gluck Glusker Godessoff Godley Goegan Gold Goldberg
Goldbloom Golden Goldfarb Goldhirsh Goldhirsh-Yellin Goldie Goldman GoldmanEvans Goldmark Goldrich Goldring Goldsmith Goldstein Goldwyn Gonen Gonor
Gonzalez Good Goodman Goodrich GoodSearch Goodshop Goodson Gordon
Gorelick Goren Gores Gorges Goring Gorleick Gottwald Graboff Grad Graiwer
Grand Grandchamp Grandstaff Grant Gray Green Greenberg Greenblatt Greenburg
Greene Greenlaw Greenlee Greenman Greenspan Greenspun Greenstein Greenstreet
Greenwald Greitzer Grennan Grey Griffin Grigsby Grindon Grob Grosfeld Gross
Grossbard Grossi Grosslight Grossman Grosvenor Gruber Gruman Grushow Guber
Guber Brufsky Guefen Guerin Guidry-Soto Gumpert Gunther Gurney Gussman
Gustavson Gutfreund Gutierrez Gutman Gutstein Gwartz Gwynn Haas Haddad
Hadidi Hahl Hahn Hainna Hall Halper Halpern Halpert Hamer Hamermesh Hamrick
Handelman Hankey Hanning Hans Hansen Harangody Harbert Harding Harewood
Harleston Harold Haroni Harris Harrower Hart Hartman Hartson Hausberg Hausfater
Hayman Hayward Heacock Health Media Heisz Hekmat Held Held Bordy Heller
Heller Gerard Helman Heltzer Hendel Henry Henschel Hensley Hermann Hermelin
Hernandez Herrick Hersh Hershler Hertz Hertzberg Herwick Herz Herzig Herzog
Herzog Millman Hess Hicks Hillman Himy Hindshaw Hinshaw Hirsch Hirschhorn
Hirsh Ho Hoberman Hochman Hochron Hodess Hofflund Hoffman Hoffner
Hofheimer Hogan Holdsworth Holland Hollander Holman Holthouse Holzer Honour
Hopkins Hopper Horky Horowitz Horton Horwich Hoshide Hotchkiss Hou Houck
Howard Huddleston Hudson Hughes Hulce Huling Hunegs Hunt Hurwitz Huvane
Hyat Hyman Ibarra Iglesias Indich Innes Insinger Iovine Isaacs Isaacson Isenberg
Ishak Isley Israel Itkin Iwafuchi Hamer Iwanyk Jackman Jackson Jackson-Zapata
Jacobs Jacobson Jacob Tuvia Jacoby Jaffe Jalali James Jamison Jandaghi Jannol
Jansen Jashni Jaynes Jeffer Jensen Jillings Joel Joelson Johann John Johnson
Johnson Tennant Johnston Joie Jolna Jones Jordan Jossen Julis Kabat Kaeser
Kagan Kahn Kalb Kalin Kalish Kaliski Kallick Kallman Kalt Kaltman Kamark
Kamins Kaner Kanter Kao Kapan Kapinos Kaplan Kapnek Brown Karaahmet
Karathanasis Karen Karmin Karp Karsh Karubian Karz Kashanian Kashefi Kassan
Kasten Katz Kaufman Kay Kaye Kayne Keating Keen Keenan Keighley Keith
Keller Kelley Kelly Kelman Kennedy Kenworthy Kershaw Kessler Ketai Keyes
Keyser Kilgallon Kinsey Kirsh Kirshbaum Kissick Kitaer-Penn Kitt McKinnon Klarman
Kleiman Klein Klein-Kabat Kleinman Klem Kliger Kline Kloves Kluiber Klutznick
Klutznik Knapp Knibb Knight Knoopf Kobylt Kocaya Koch Koenig Kohan Kohl
Kokozos Kolbrenner Komberg Kong Konheim Kono Kopczynski Kopf Kors Kort
Kortschak Korzen Kosove Kostow Kotick Kotler Kouba Koulias Kozberg Kradin
Kraines Kramer Krane Krantz Kranz Krask Krasnow Kraus Kravitz Kreikemeier
Kreisberg Kreitenberg Kremen Kresek Kreshek Krevoy Kriegel Kruszenski Krzynowek
Kudrow Kuhny Kumble Kuperman Kurlandsky Kurtz Kurtzman Kushner Kwatinetz
LaBrecque Lachman Lacy Ladenheim Lafferty Laille Laine Lainer Lakin Lambeth
Lampert Landaw Lande Lander Landes Landon Lane Langone Langos Lansing
Lanza Lapin Larbalestier Lasker Lassally Latorre Latt Latter Latt Wiatt Laurie
Lautman Lavinthal Lavoie Lawrence Lawson Lax Layne Lazar Lazaruk Leader
LeBauer Lebow Lebowitz Lechter Leder Lederer Lederer Wells Lederman Lee
Leeds Leevan Leff Lefkowitz Lehrman Leibovitch Leibowitz Leichtman Leigh Leipart
Leiter Lembo Lemelson Lenihan Lentz Leonard LeRay Levant Levenstein Levin
Levine Levine-Blonder Levinson Levisetti Levite Levitt Levy Lewis Lewitt Leyrer
Leyva Lezak Liau Liber Licht Lichtenstein Licker Lieberman Liebling Liguori Limor
Lincenberg Lincoln Lindee Linehan Liner Lipman Lippert Lippman Lipsett Lipshutz
Lipsic Lipsky Buch Lipsztein Lis Listen Litman Littman Litvack Litvak Litwak Litwin
Liu Living Livingston Lloyd Lobel Loewenthal London Longstreet Lonner Loparty
Lopez Lopper Lord Lorenzen Losito Loskota Lotman Louchheim Louie Lourd Lovett
Lowenstein Lowry Lowy Lu Lubens Lublin Lucas Luchs Lukoff Luna Lundy Lurie
Lurie Spetner Luskin Lustig Luxenberg Lynch Lyon Lyons Mack Mackey MacRae
Mahl Mahmood Mahmoodzadegan Maiman Mallory Maloney Mancino Mandel
Mandelbaum Mann Mansaury Manze Mapes Marantz Marchetti Marciano Marcil
Marcus Marek Margolis Mariano Marin Marinova Markman Markowitz Marks Marmur
Maron Marquinez Marsh Marshall Martin Martin DeLuca Martinez Masin Mason
Massman Masters Masuda Mathes Mathews Matloff Matsuhisa Matus Matz
Mavredakis Maxima Maxwell Maybank Mayer Mayfield Junior School Mayman Mazirow
Mazur
Mazursky
McCabe
McCain-Tharnstrom
McCartney
McCorduck
McCoy
McCubbin McDonald McDonnell McEvoy McGinley McGovern McGrath McMillan
McMorrow McMullin McNamara McNitt McPhearson McPherson McStay Meadow
Meadow Phillips Meehan Mehrens Mehta Melamed Meleo-Bernstein Mellon Melman
Melmed Meltzer Menard Mendelsohn Mendelson Mercer Merin Merrill Merriman
Messick Messing Messinger Metropolis Retail Inc. Metzinger Meyer MGL Michelman
and Robinson Michelson Milken Milken Bernstein Millard Miller Millman Mills Milstein
Minas Mindel Mindlin Minerd Mintzer Mintz Gathrid Mirkin Miskei Missaghieh Mitchell
Mitteldorf Mizel Mobasseri Moelis Moffitt Mogel Mogy Mohr Moir Moiseeff Mayman
Monestere Monkarsh Monroe Montalba Montgomery Montminy Montrone Moore
Moran Moray Moreno Greenlee Morgan Morgerman Morguelan Moriarty Moritz Morris
Morrish Morrison Morrissey Morse Lebow Mortell Morton Mosbat Moss Moursi
Mozur Mueller Muldoon Mullen Mulvehill Munoz Murawa Murphy Murray Myers
Myerson Myman Nachtomi Nadel Nadrich Naegele Naficy Naft Naftali Naftzger
Nakaoka Nanji Nathan Nathan Family Foundation Nathanson Natterson Navarre
Nazarian Nederlander Neiman Nellor Nelson Neman Nemeroff Nesbitt Neufeld
Neumann Newberg Newfield Newlander Newman Newton Howard Ngo Nichol Nickoll
Nicolayevsky Nicole Nicoletti Nicoll Nii Nix Nordstrom Norris Nossel Novick Nunan
Nyman Oakes Slavich O'Brien O'Connor Offer Offsay Ohlmeyer Oillataguerre Oks
Okum Olan Olofson Olshansky Olson O'Malley O'Mara O'Neil Onen Oppenheim
Optican Orser Osterhout Ostin Ostroff Ostrow Oswaks Otte Overholser Owen
Owens Paasche Pack Paget Paik Painter Pakula Palermo Palinkov Palmer
Papalian Parker Parks Parnell Parsa Parvaresh Parzen Passman Pattison Paul
Paulsen Pauly Paura Paykos Payne Peacock Pearlman Pearson Pecaut Peecook
Peele Pelayo Peloso Peltz Penner Penske Pepp Perenchio Perison Perkins
Perlman Permut Pernice Perry Peters Petersen Peterson Petschek Pfeffer Phelps
Phillips Phu Pian Piantadosi Piccioni Piccirillo Pickel Barger Piehl Pierson Pina
Pinchus Pinkner Piro Pistor Pitt Platt Platz Plonsker Plunkett Plutsky Po Pogue
Polak Policella Polidoro Polinsky Pollack Pollack Fox Polson Polster Polster Hankey
Pomerance Pomerantz Pomeroy Pompan Pooya Popofsky Kramer Porter Posnick
Post Poster Powell Poyer Prather Praw Presant Pretlow Price Prins Pritzker
Prober-Cohen Prost Prudente Prunier Pulier Pullman Puopolo Purcelli Puri Quaranta
Quigley Quint Rabbani Rabineau Rabow Racujee Rader Radow Radzik Radziner
Rago Raich Raiher Raimi Raissen Raker Ramberg Ramser Ramsey Rams Football
Ranan Randall Randolph Rankin Ransohoff Rapaport Rappaport Rasansky Rassell
Ratner Rautbort Ravich Ravich McNitt Rawjee Ray Redlin Reece Reed Regas
Reid Reilly Reims Reinfeld Reisman Reiter Resch Resnick Resnikoff Ressler
Reubel Revitz Reznick Rhee Hindshaw Rhein Rhode Rhodes Rice Riceberg Rich
Richards Richards Sachs Richbook Richker Richman Richter Riddell Riepe Riera
Rierson Rifkin Riggs Riley Risko Ritter Simon Rivera Robbins Roberts Roberts
Freeman Robinson Robles Robson Rocchio Rockwell Rodan Rodgers Rodriguez
Rogers Rohde Roll Giving Romano Romick Romm Roos Rose Rosedale Rose
Foundation Rosen Rosenbaum Rosenberg Rosenblood Rosenbloom Rosenblum
Rosenfeld Rosenfield Rosenthal Ross Rossen Rosti Rotell Rotenberg Roth
Rothenberg Rothfeld Rothman Rotner Rousselot Roveda Rowen Royce Rozelle
Rubaum Rubin Ruderman Rudnai Rudnick Rush Rusk Russakoff Russel Ford
Russell Russo Ruxin Ryan Ryback Rylance Sabah Sabel Sachs Sachse Sack
Sacks Saevitzon Saferstein Saha Sahlein Saidinia Sain Sakalis Salathe Saliman
Salka Sall Salo Salzman Samek Samuel Sanchez Sanchez-Lazer Sanchini
Sandekian Sanders Sandler Sands Sanger Sanitsky Santos Saperstein Sarkisian
Sarnoff-Ross Saslow Sassaman Sassi Satchu Saunders Schaer Schaffer Scharkss
Schechter Scheck Scheckter Scheetz Schenkel Schenkman Scher Schettig Schiff
Schinderman Schlessel Schlessinger Schneider Schneiderman Schnider Schoelen
Schotz Schrage Schrager Schreiber Schubach Schwartz Schweitzer Schwimmer
Scott Seabold Seacrest Second Street Seeburger Segal Segel Segor Seitz Selby
Sellers Semel Serber Sertner Serviss Sexton Shabani Shadyac Shafer Shagrin
Shams Shanfeld Shanus Shapiro Sharifi Sharpe Shearmur Sheets Sheinberg
Sheinfeld Sher Sheresky Sherman Sherwood Sheth Shilling Shine Shirinyaw Shlafer
Shoenfeld Shokrian Sholem Shore Shpelfogel Shpiner Shriver Shrum Shulman
Shuman Shuster Siciliao Siebert Siegel Siegler Siegler Rothberg Sieveking Sigal
Sigoloff Silber Silberkleit Silberling Silberman Silberstein Silbert Silfen Silverman
Silvers Silverstein Silverton Simchowitz Simon Simonds Simone Simonian Simons
Sims Wood Sind Sindell Singer Singh Sirulnick Sischo Sisino Sisteron Sixx Skerik
Skoro Skvarla Skylar Slater Slatkin Slavich Sloane Slobin Slocum Slomowitz Small
Smidt Smilen Smith Smolberg Smolin Smolinisky Smooke Snider Snyder Soares
Sobel Sofro Sohayegh Baradarian Soh Woods Sokol Sokoloff Solnit Solomon Solov
Solton Somer Somers Sones
Soni-Mehta Soofer Sorkin Soros Sorotzkin Soto
Spaeth Spalding Spector Spectrum Spetner Spezio Spiegel Spilka Spink Spinner
Spiro Spitz Sponco Spound Sprung Spungin Spyksma Sraberg Sri-Kumar Staggs
Stahman Stamen Arrillaga Stanley Stark Starkman Stearn Stearns Stein Steinberg
Steiner Steinfeld Stelzer Sterling Stern Stevens Stewart Stoff Stokdyk Stolaroff
Stone Stowell Ford Straberg Strasmore Strauss Strempek Strickler Studebaker Stupp
Styne Suddleson Sudikoff Sue Sugar Sugarman Sugerman Sukkert Sunkin Suskin
Susskind Sussman Sutton Swalwell Swan Swanky Swanson Swardstrom Swartz
Swedlin Sweeney Swiller Swindells Sykes Tabach-Bank Takowsky Tanenbaum
Tannenbaum Tapper Tarin Tarnofsky-Ostroff Tarses Tashman Tate Tavangarian
Tavares Taylor Tebbe Meyer Tehrani Teiger Temkin Tenebaum Tennant Tenner
Tenzer Tessler Tharnstrom Theony Thom Thomas Thomopoulos Thompkin-Dobkin
Thompson Thorne Thorson Thurnher Tidyman Tiger Tilchin Tile with Style Tilkian
Tippl Tipton Tisch Titan Tobey Todd Tolkin Tollman Tolot Tolson Toplitzky Toppel
Towner Townsend Tractenberg Tracy Tranen Tratchenberg Trattner Treadwell Trepp
Trewhitt Trostler Tsabag Tucker Tuckman Tuli Turkell Turnbull Turner Turteltaub
Tuvia Twilley Uchikura Ullman Umansky Unger Upchurch Uslaner Uzielli Vahn
Vaiman Valentine Valner Van de Bunt Van Donge Vaneckert Van Gilder Vann Varney
Velkes Vella Venit Venturelli Verdadero Vertoch Vetter Victor Vidergauz Vimeo
Vincent Viola Volpert Von Wooster Vorhoff Vradenburg Wachtel Waddler Wadler
Wagman Wagmeister Wagner Wahlstrom Walden Waldstein Walentas Walker
Wallace Wallach Wallach Kleinman Walston Wander Wang Ward Wardle Warren
Wasser Wasserman Waxman Wearstler Webb Webber Weber Webster Wechsler
Wecker Weed Weetman Weg Weide Weidenfeller Weil Weiman Weinberg
Weinberger Weiner Weingarten Weinstein Weinstock Weintraub Weisbarth Weisberg
Weisenberg Weiser Weisman Weiss Weissberg Weisskopf Weissman Weitman Weitz
Weitzman Welch Wells Welsh-Hanning Wenokur Wertheimer Wexler Whalen
Wheeler Whipple Whitebook Whitesell Whitman Whittaker Wick Wiczyk Wilchfort
Wild Wilf William Williams Wilson Wilstein Wimer Winebaum Winkler Winnick
Winsberg Winston Winter Winters Winton Wintrob Witenberg Witham Witherspoon
Witmer Witten Wolcott Wolens Wolf Wolfen Wolff Wolf Klein Wolk Wolken Wong
Woo Wood Woodruff Woods Woodward Woolfe Worchell Woronoff Wozniak Wright
Wrigley Wrublin Wyman Wynn Yaffe Yagan Yamarone Yanow Yaw Yazedjian
Yellin Yip Youd Young Younger Yuhashi Yung Zafran Zaga Zaharia Zahn Zajfen
Zalaznick Zanuck Zanville Zapata Zara-Kobylt Zarnegin Zeegen Zeiden Ziering
Ziffren Zifkin Zilber Zimbert Zimmer Zimmerman Zinberg Zinman Kohl Zislis Zisman
Zohar Zoller Zommick Zubery Zuckerman Zukor Zundelevich Zuriff Zwahlen Zweben
Zwick Zwillinger
STAYING IN TOUCH
Learn more about PHASE ONE, including our latest grants,
upcoming events and news about cancer research.
•••
FACEBOOK • INSTAGRAM • TWITTER
@PhaseOneLA
•••
256 - 26th Street, Suite 201
Santa Monica, CA 90402
310-458-7715 phone
310-393-6051 or 818-505-9170 fax
www.phaseonefoundation.org
[email protected]
Thank you for being
th
part of our 15 Gala &
our Virtual Journal
• • •
You DID support
PHASE ONE

2015 Journal

Transcription

Similar documents

5 Marina Terra - Seaside Realty

Hawaiian Champagne Brunch

Foreword - touchONCOLOGY

19 Marina Terra - Seaside Realty

10 Marina Terra - Seaside Realty

Marina Terra 303

108 Marina Terra

CvSSS

An expression of gratitude for all our moments.

Exsanguination - Northern Health

TRICENTENARI Presentació ICO - Portal e